Yan 2001.

Methods	Inclusion: Eligible participants had to meet the following criteria: pathology‐ and cytology‐confirmed locally advanced or metastatic NSCLC (stage IIIA to IV); Karnofsky score ≥ 60; life expectancy > 3 months; adequate haematological, hepatic, and renal function. Exclusion: No exclusion criteria were specified for this study.
Participants	Arm I: 61 people Arm II: 65 people
Interventions	Arm I: paclitaxel (175 mg/m2) iv on day 1 and carboplatin (350 mg/m2) on day 1, every 4 weeks Arm II: paclitaxel (175 mg/m2) iv on days 1 and 8 and cisplatin (100 mg/m2) on day 1, every 4 weeks
Outcomes	Primary outcomes: response rate toxicity Secondary outcomes: 1‐year survival overall survival
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were stratified according to sex and staging.
Allocation concealment (selection bias)	Unclear risk	No clear description of randomisation provided in the publication.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information about blinding process
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information about blinding process
Incomplete outcome data (attrition bias) All outcomes	Low risk	No evidence of incomplete outcome data
Selective reporting (reporting bias)	Low risk	No evidence of selective reporting bias
Other bias	High risk	The dose of carboplatin was 350 mg/m2 iv on day 1, which differs from the doses used in almost all the other included trials (AUC 4 to 6 mg/mL X minutes).